Project Grant R43HG013476
Award Date
8/1/23
Completion Date
7/31/24
Dollars Obligated
$407K
Federal Agency
National Human Genome Research Institute
Awardee
JBS Science Inc. (DG7YFQJF7UJ5)
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $269,154 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Chicago. The grant aims to characterize the genome-wide 5-hydroxymethylcytosine (5hmC) landscape of healthy urine cell-free DNA (cfDNA) and develop biomarkers for localized bladder cancer diagnosis and prognosis. Key objectives include optimizing a bioinformatics pipeline to analyze 5hmC profiles in urine cfDNA, identifying tissue-of-origin, and...
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a novel bladder cancer diagnostic assay called BCDX. The $821,797 award to Early IS Good, Inc. aims to execute a clinical validation study for BCDX, which uses advanced nanotechnology to detect twelve different biomarkers from a urine sample, including proteins, miRNAs, mRNAs, and lncRNAs. The comprehensive, multi-omic and...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The goal of this 1-year project is to develop a novel nanopore-based sequencing approach that can accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Icahn School of Medicine at Mount Sinai to conduct a multi-scale analysis of the Bacillus Calmette-Guerin (BCG) resistant tumor microenvironment in non-muscle invasive bladder cancer. The $684,877 award, with a project period from April 2025 to March 2030, will leverage single-cell and spatial sequencing techniques across 36 samples to elucidate the cellular, genomic, and...
The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $3,377,867 Project Grant to Survey Genomics, Inc. on September 19, 2024. The grant supports the development and commercialization of the CYTOPE-DROP platform, an innovative approach for spatially-resolved single-cell multiomics analysis. Key features of the CYTOPE-DROP technology include: 1) high-throughput capacity to localize individual cells and obtain their...
The National Human Genome Research Institute (NHGRI) awarded a $383,482 Project Grant under the Human Genome Research federal grant program (CFDA 93.172) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant, awarded on June 6, 2025, aims to develop SPINSEQ, an innovative platform designed to deliver highly precise and accurate RNA sequencing. The project will focus on maintaining RNA integrity and ensuring precise sequencing, with a particular...
The National Human Genome Research Institute (NHGRI), under the Federal Grant Program "Human Genome Research" (CFDA 93.172), awarded a $407,291 Phase I Small Business Innovation Research (SBIR) grant to Electronic Biosciences, Inc. to develop a nanopore-based protein sequencing platform. The project aims to create a high-accuracy, label-free nanopore reader capable of direct, single-molecule protein sequencing. This novel technology would enable proteome-wide profiling, biomarker...
The National Human Genome Research Institute (NHGRI), through its Human Genome Research Program (CFDA 93.172), awarded a $1,247,028 Project Grant to Cantata Bio LLC, a small business based in California. The grant, awarded on September 18, 2024, supports the development and commercialization of Cantata Bio's innovative "VariLink" Hi-C platform for sensitive genomic profiling of multiple cancer sample types. The VariLink technology is designed to overcome limitations of current...
This $400,000 Project Grant award from the National Human Genome Research Institute (NHGRI) under CFDA 93.172 "Human Genome Research" will support a research program at Brigham & Women's Hospital to develop advanced computational methods for accurately identifying and genotyping structural variants within large genetic biobank datasets. The key objectives of the work are to: 1) create haplotype-informed algorithms to improve detection sensitivity and genotyping accuracy for...